Premium
Cyp1 Inhibition Prevents Doxorubicin‐Induced Cardiomyopathy in a Zebrafish Heart‐Failure Model
Author(s) -
Lam PuiYing,
Kutchukian Peter,
Anand Rajan,
Imbriglio Jason,
Andrews Christine,
Padilla Hugo,
Vohra Anita,
Lane Sarah,
Parker Dann L.,
Cornella Taracido Ivan,
Johns Douglas G.,
Beerens Manu,
MacRae Calum A.,
Caldwell John P.,
Sorota Steve,
Asnani Aarti,
Peterson Randall T.
Publication year - 2020
Publication title -
chembiochem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.05
H-Index - 126
eISSN - 1439-7633
pISSN - 1439-4227
DOI - 10.1002/cbic.202000353
Subject(s) - zebrafish , doxorubicin , heart failure , cardiomyopathy , in vivo , pharmacology , cardiotoxicity , medicine , chemistry , cancer research , cardiology , chemotherapy , biology , biochemistry , gene , genetics
Cyp1 inhibition prevents doxorubicin‐induced cardiomyopathy in a zebrafish heart‐failure model. Doxorubicin, a potent chemotherapy drug, has a side effect of inducing heart failure. By using a zebrafish doxorubicin‐induced cardiomyopathy model for in vivo small‐molecule screening, the cytochrome P450 family (CYP1) was identified as a candidate therapeutic target for clinical cardioprotection. More information can be found in the full paper by R. T. Peterson et al.